Welcome to our dedicated page for Nkarta SEC filings (Ticker: NKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nkarta, Inc. (NASDAQ: NKTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nkarta is a clinical-stage biotechnology and biopharmaceutical company developing engineered, allogeneic, off-the-shelf NK cell therapies for autoimmune diseases, and its SEC filings offer structured insight into how it reports financial results, clinical progress, and key risks to investors.
Nkarta’s recent Form 8-K filings include press releases announcing quarterly financial results, where the company discusses research and development expenses, general and administrative expenses, net loss, and its cash position. These 8-Ks also reference Nkarta’s status as an emerging growth company and point to more detailed risk factor sections in its Form 10-K and Form 10-Q reports.
Through its periodic filings, Nkarta describes the clinical development of its lead NK cell therapy candidate NKX019, including its use in Ntrust-1 and Ntrust-2 autoimmune disease trials and investigator-sponsored studies. The company’s filings outline factors such as limited operating history, lack of approved products, dependence on NKX019, clinical trial timing, manufacturing complexity for CAR NK therapies, and reliance on third parties, which it identifies as key business and development risks.
On Stock Titan, Nkarta’s SEC filings are updated as new documents are posted to the EDGAR system. AI-powered summaries help explain the main points of lengthy filings, highlight changes from prior reports, and surface items such as financial condition discussions and risk factor updates. Users can quickly review 8-Ks related to earnings announcements and use the platform’s tools to understand how Nkarta’s disclosures connect to its NK cell therapy pipeline and autoimmune disease focus.
Nkarta reported a significant insider transaction involving Chief Medical Officer and Head of R&D, Shawn Marshall Rose. On June 23, 2025, Rose was granted stock options to purchase 500,000 shares of common stock at an exercise price of $1.75 per share.
The stock options have a structured vesting schedule:
- 25% of the options vest on July 23, 2026
- Remaining 75% vest in 36 equal monthly installments following June 23, 2026
- Options expire on June 22, 2035
This grant suggests a long-term retention strategy for a key executive, with the low exercise price potentially indicating recent stock price challenges or an incentive-focused compensation structure. The substantial size of the grant (500,000 shares) reflects the senior leadership position and importance of the R&D function to the company.
Form 3 Initial Statement of Beneficial Ownership filed for Nkarta (NKTX) on June 28, 2025, reporting the beneficial ownership status of Shawn Marshall Rose, who has been appointed as the company's Chief Medical Officer and Head of Research & Development.
Key details:
- Filing Date: June 28, 2025
- Event Date: June 23, 2025
- Location: South San Francisco, CA
- Filing Type: Individual filing
- Current Holdings: No securities beneficially owned
This Form 3 indicates that the executive currently holds no derivative or non-derivative securities in the company. The filing was signed by Bridgette Housley as Attorney-in-Fact on June 25, 2025, and includes a Power of Attorney as Exhibit 24.
Nkarta, Inc. (NKTX) – Form 4 Insider Transaction Overview
CEO and Director Paul J. Hastings disclosed the sale of 1,790 common shares on 06/18/2025 at a weighted-average price of $1.79. The transaction was automatically executed to satisfy tax-withholding obligations triggered by the vesting and settlement of Restricted Stock Units and therefore was not a discretionary sale. Following the sale, Hastings continues to beneficially own 320,069 shares, which includes 2,000 shares purchased under Nkarta’s 2020 Employee Stock Purchase Plan on 05/31/2025.
No derivative securities were acquired or disposed of, and no additional transactions were reported. Given the small size of the sale—roughly 0.56% of the executive’s total holdings—the filing appears routine and does not signal any change in corporate strategy, financial position, or insider sentiment.